Robert Dzialo is a partner in the firm’s Technology group. Mr. Dzialo advises clients on a wide array of corporate matters, including mergers and acquisitions, venture capital and growth equity financings, public securities offerings, corporate restructurings and other strategic transactions. He also represents a number of publicly traded companies and investment funds in ongoing SEC compliance matters. He joined Goodwin in 2014 and is a member of the firm’s hiring committee.

While attending law school, Mr. Dzialo served as a senior editor for the Boston College Law Review.

Areas of Practice
Domaines D’Expertise





Mr. Dzialo’s client representations include:

Mergers and Acquisitions

Strategic Acquisitions

  • PillPack in its sale to
  • Kabbage in its sale to American Express
  • Padlock Therapeutics in its $600 million sale to Bristol-Meyers Squibb
  • Sqrrl Data in its sale to
  • in its sale to Facebook
  • HubSpot in its acquisition of PieSync
  • Handy Technologies in its sale to Angie’s List
  • PlumChoice in its sale to Allstate

Financial Acquisitions

  • Monotype in its $825 million sale to private equity firm HGGC
  • Acquia in its sale to Vista Equity Partners
  • RedBrick Health in its sale to Marlin Equity Partners
  • Continuum in its sale to Thoma Bravo

Private Financings

  • Bessemer Venture Partners in its equity financing of viagogo in connection with its acquisition of StubHub from eBay
  • BridgeBio Pharma in its $300M million preferred equity financing led by KKR and Viking Global
  • Century Therapeutics in its $250 million financing led by Bayer
  • CLEAR in its equity financing and strategic collaboration with United Airlines
  • DRIVE by DraftKings in its collaboration with DraftKings, General Catalyst, Accomplice and Boston Seed
  • Cybereason in its $100 million Series D preferred stock financing with SoftBank
  • Momofuku in its preferred equity financing with RSE Ventures

Public Offerings

  • Underwriters in Endurance International Group’s follow-on public offerings raising a total of $479 million
  • AMAG Pharmaceuticals in numerous follow-on equity offerings and its high-yield bond offering
  • BridgeBio in its $372 million initial public offering


Mr. Dzialo has been recognized by The Best Lawyers in America Ones to Watch for his work in Corporate Law 2022.

Mr. Dzialo was named to The Best Lawyers in America 2021: Ones to Watch.

In The News









J.D., 2014
Boston College
(magna cum laude)
B.A., 2010
James Madison University
(magna cum laude)



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique